Survey Outcome on Immunogenicity Risk Assessment Tools for Biotherapeutics: an Insight into Consensus on Methods, Application, and Utility in Drug Development.
biotherapeutic
harmonization
immunogenicity risk
in vitro assay
preclinical development
reference materials
Journal
The AAPS journal
ISSN: 1550-7416
Titre abrégé: AAPS J
Pays: United States
ID NLM: 101223209
Informations de publication
Date de publication:
02 06 2023
02 06 2023
Historique:
received:
20
03
2023
accepted:
12
05
2023
medline:
5
6
2023
pubmed:
2
6
2023
entrez:
2
6
2023
Statut:
epublish
Résumé
A survey conducted by the Therapeutic Product Immunogenicity (TPI) community within the American Association of Pharmaceutical Scientists (AAPS) posed questions to the participants on their immunogenicity risk assessment strategies prior to clinical development. The survey was conducted in 2 phases spanning 5 years, and queried information about in silico algorithms and in vitro assay formats for immunogenicity risk assessments and how the data were used to inform early developability effort in discovery, chemistry, manufacturing and control (CMC), and non-clinical stages of development. The key findings representing the trends from a majority of the participants included the use of high throughput in silico algorithms, human immune cell-based assays, and proteomics based outputs, as well as specialized assays when therapeutic mechanism of action could impact risk assessment. Additional insights into the CMC-related risks could also be gathered with the same tools to inform future process development and de-risk critical quality attributes with uncertain and unknown risks. The use of the outputs beyond supporting early development activities was also noted with participants utilizing the risk assessments to drive their clinical strategy and streamline bioanalysis.
Identifiants
pubmed: 37266912
doi: 10.1208/s12248-023-00820-7
pii: 10.1208/s12248-023-00820-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
55Informations de copyright
© 2023. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists.
Références
Walsh RE, Lannan M, Wen Y, Wang X, Moreland CA, Willency J, et al. Post-hoc assessment of the immunogenicity of three antibodies reveals distinct immune stimulatory mechanisms. mAbs. 2020;12(1):1764829.
Jenkins MK, Moon JJ. The role of naive T cell precursor frequency and recruitment in dictating immune response magnitude. J Immunol. 2012;188(9):4135–40.
doi: 10.4049/jimmunol.1102661
pubmed: 22517866
Delluc S, Ravot G, Maillere B. Quantitative analysis of the CD4 T-cell repertoire specific to therapeutic antibodies in healthy donors. FASEB J. 2011;25(6):2040–8.
doi: 10.1096/fj.10-173872
pubmed: 21368101
Hamze M, Meunier S, Karle A, Gdoura A, Goudet A, Szely N, et al. Characterization of CD4 T cell epitopes of infliximab and rituximab identified from healthy donors. Front Immunol. 2017;8:500.
doi: 10.3389/fimmu.2017.00500
pubmed: 28529511
pmcid: 5418239
Ducret A, Ackaert C, Bessa J, Bunce C, Hickling T, Jawa V, et al. Assay format diversity in pre-clinical immunogenicity risk assessment: toward a possible harmonization of antigenicity assays. MAbs. 2022;14(1):1993522.
doi: 10.1080/19420862.2021.1993522
pubmed: 34923896
Deora A, Hegde S, Lee J, Choi CH, Chang Q, Lee C, et al. Transmembrane TNF-dependent uptake of anti-TNF antibodies. MAbs. 2017;9(4):680–95.
doi: 10.1080/19420862.2017.1304869
pubmed: 28323513
pmcid: 5419086
Xue L, Hickling T, Song R, Nowak J, Rup B. Contribution of enhanced engagement of antigen presentation machinery to the clinical immunogenicity of a human interleukin (IL)-21 receptor-blocking therapeutic antibody. Clin Exp Immunol. 2016;183(1):102–13.
doi: 10.1111/cei.12711
pubmed: 26400440
Wen Y, Cahya S, Zeng W, Lin J, Wang X, Liu L, et al. Development of a FRET-based assay for analysis of mAbs internalization and processing by dendritic cells in preclinical immunogenicity risk assessment. AAPS J. 2020;22(3):68.
doi: 10.1208/s12248-020-00444-1
pubmed: 32300899
Jawa V, Terry F, Gokemeijer J, Mitra-Kaushik S, Roberts BJ, Tourdot S, et al. T-cell dependent immunogenicity of protein therapeutics pre-clinical assessment and mitigation–updated consensus and review 2020. Front Immunol. 2020;11(1301):1–23.
Murphy K, Casey W. Janeway’s Immunobiology. Ninthe. New York: Garland Science; 2017.
Wen Y, Jawa V. The impact of product and process related critical quality attributes on immunogenicity and adverse immunological effects of biotherapeutics. J Pharm Sci. 2021;110(3):1025–41.
doi: 10.1016/j.xphs.2020.12.003
pubmed: 33316242
Jarvi NL, Balu-Iyer SV. Immunogenicity challenges associated with subcutaneous delivery of therapeutic proteins. BioDrugs. 2021;35(2):125–46.
doi: 10.1007/s40259-020-00465-4
pubmed: 33523413
pmcid: 7848667
Colella P, Ronzitti G, Mingozzi F. Emerging issues in AAV-mediated in vivo gene therapy. Mol Ther Methods Clin Dev. 2018;8:87–104.
doi: 10.1016/j.omtm.2017.11.007
pubmed: 29326962
Grimaldi C, Finco D, Fort MM, Gliddon D, Harper K, Helms WS, et al. Cytokine release: a workshop proceedings on the state-of-the-science, current challenges and future directions. Cytokine. 2016;85:101–8.
doi: 10.1016/j.cyto.2016.06.006
pubmed: 27309676
Shimabukuro-Vornhagen A, Gödel P, Subklewe M, Stemmler HJ, Schlößer HA, Schlaak M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):56.
doi: 10.1186/s40425-018-0343-9
pubmed: 29907163
pmcid: 6003181
Vessillier S, Eastwood D, Fox B, Sathish J, Sethu S, Dougall T, et al. Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials–whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm. J Immunol Methods. 2015;424:43–52.
doi: 10.1016/j.jim.2015.04.020
pubmed: 25960173
pmcid: 4768082
Finco D, Grimaldi C, Fort M, Walker M, Kiessling A, Wolf B, et al. Cytokine release assays: current practices and future directions. Cytokine. 2014;66(2):143–55.
doi: 10.1016/j.cyto.2013.12.009
pubmed: 24412476
Vessillier S, Fort M, O’Donnell L, Hinton H, Nadwodny K, Piccotti J, et al. Development of the first reference antibody panel for qualification and validation of cytokine release assay platforms - report of an international collaborative study. Cytokine X. 2020;2(4): 100042.
doi: 10.1016/j.cytox.2020.100042
pubmed: 33458650
pmcid: 7789043
Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188–95.
doi: 10.1182/blood-2014-05-552729
pubmed: 24876563
pmcid: 4093680
Quarmby V, Phung QT, Lill JR. MAPPs for the identification of immunogenic hotspots of biotherapeutics; an overview of the technology and its application to the biopharmaceutical arena. Expert Rev Proteomics. 2018;15(9):733–48.
doi: 10.1080/14789450.2018.1521279
pubmed: 30198337
Kropshofer H, Singer T. Overview of cell-based tools for pre-clinical assessment of immunogenicity of biotherapeutics. J Immunotoxicol. 2006;3(3):131–6.
doi: 10.1080/15476910600845625
pubmed: 18958693
Paul S, Lindestam Arlehamn CS, Scriba TJ, Dillon MB, Oseroff C, Hinz D, et al. Development and validation of a broad scheme for prediction of HLA class II restricted T cell epitopes. J Immunol Methods. 2015;422:28–34.
doi: 10.1016/j.jim.2015.03.022
pubmed: 25862607
pmcid: 4458426
Zinsli LV, Stierlin N, Loessner MJ, Schmelcher M. Deimmunization of protein therapeutics - recent advances in experimental and computational epitope prediction and deletion. Comput Struct Biotechnol J. 2021;19:315–29.
doi: 10.1016/j.csbj.2020.12.024
pubmed: 33425259
Moise L, Song C, Martin WD, Tassone R, De Groot AS, Scott DW. Effect of HLA DR epitope de-immunization of factor VIII in vitro and in vivo. Clin Immunol. 2012;142(3):320–31.
doi: 10.1016/j.clim.2011.11.010
pubmed: 22222093
Ridker PM, Tardif JC, Amarenco P, Duggan W, Glynn RJ, Jukema JW, et al. Lipid-reduction variability and antidrug-antibody formation with Bococizumab. N Engl J Med. 2017;376(16):1517–26.
doi: 10.1056/NEJMoa1614062
pubmed: 28304227
Hua F, Comer GM, Stockert L, Jin B, Nowak J, Pleasic-Williams S, et al. Anti-IL21 receptor monoclonal antibody (ATR-107): safety, pharmacokinetics, and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study. J Clin Pharmacol. 2014;54(1):14–22.
doi: 10.1002/jcph.158
pubmed: 23913720
Welt S, Ritter G, Williams C Jr, Cohen LS, John M, Jungbluth A, et al. Phase I study of anticolon cancer humanized antibody A33. Clin Cancer Res. 2003;9(4):1338–46.
pubmed: 12684402
Stern LJ, Santambrogio L. The melting pot of the MHC II peptidome. Curr Opin Immunol. 2016;40:70–7.
doi: 10.1016/j.coi.2016.03.004
pubmed: 27018930
pmcid: 4884503
Jiskoot W, Kijanka G, Randolph TW, Carpenter JF, Koulov AV, Mahler HC, et al. Mouse models for assessing protein immunogenicity: lessons and challenges. J Pharm Sci. 2016;105(5):1567–75.
doi: 10.1016/j.xphs.2016.02.031
pubmed: 27044944
pmcid: 4846475
Wickramarachchi D, Steeno G, You Z, Shaik S, Lepsy C, Xue L. Fit-for-purpose validation and establishment of assay acceptance and reporting criteria of dendritic cell activation assay contributing to the assessment of immunogenicity risk. AAPS J. 2020;22:114.
Wullner D, Zhou L, Bramhall E, Kuck A, Goletz TJ, Swanson S, et al. Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics. Clin Immunol. 2010;137(1):5–14.
doi: 10.1016/j.clim.2010.06.018
pubmed: 20708973
Jawa V, Cousens LP, Awwad M, Wakshull E, Kropshofer H, De Groot AS. T-cell dependent immunogenicity of protein therapeutics: preclinical assessment and mitigation. Clin Immunol. 2013;149(3):534–55.
doi: 10.1016/j.clim.2013.09.006
pubmed: 24263283
Bertolini TB, Shirley JL, Zolotukhin I, Li X, Kaisho T, Xiao W, et al. Effect of CpG depletion of vector genome on CD8(+) T cell responses in AAV gene therapy. Front Immunol. 2021;12: 672449.
doi: 10.3389/fimmu.2021.672449
pubmed: 34135899
pmcid: 8200677
Konkle BA, Walsh CE, Escobar MA, Josephson NC, Young G, von Drygalski A, et al. BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression. Blood. 2021;137(6):763–74.
doi: 10.1182/blood.2019004625
pubmed: 33067633
pmcid: 7885820
Wright JF. Codon modification and PAMPs in clinical AAV vectors: the tortoise or the hare? Mol Ther. 2020;28(3):701–3.
doi: 10.1016/j.ymthe.2020.01.026
pubmed: 32035026
pmcid: 7054817
Verdera HC, Kuranda K, Mingozzi F. AAV vector immunogenicity in humans: a long journey to successful gene transfer. Mol Ther. 2020;28(3):723–46.
doi: 10.1016/j.ymthe.2019.12.010
pubmed: 31972133
pmcid: 7054726
Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood. 2013;122(1):23–36.
doi: 10.1182/blood-2013-01-306647
pubmed: 23596044
pmcid: 3701904
FDA (2014) Guidance for industry: immunogenicity assessment for therapeutic protein products. https://www.fda.gov/media/85017/download . Accessed on April 25, 2021.
Siegel M, Steiner G, Franssen LC, Carratu F, Herron J, Hartman K, et al. Validation of a dendritic cell and CD4+ T cell restimulation assay contributing to the immunogenicity risk evaluation of biotherapeutics. Pharmaceutics. 2022;14:2672.
Cohen S, Myneni S, Batt A, Guerrero J, Brumm J, Chung S. Immunogenicity risk assessment for biotherapeutics through in vitro detection of CD134 and CD137 on T helper cells. MAbs. 2021;13(1):1898831.
doi: 10.1080/19420862.2021.1898831
pubmed: 33729092
pmcid: 7993230